Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Cardiovascular Actions and Clinical Outcomes With GLP-1 Receptor Agonists and DPP-4 Inhibitors
GLP-1s are unlikely to deliver therapeutic value when so many individuals stop treatment after two years, but the findings also illustrate the need for obesity care management programs to improve adherence. Prime/MRx has been at the forefront of GLP-1 insights since we released our year-one research, and though we continue to see declines in persistence and adherence, we are committed to providing clients with actionable data and insights that can steer positive health outcomes for individuals. David Lassen, chief clinical officer David Lassen, chief clinical officer While real-world data is central to discussions about affordability and access, especially as the popularity of GLP-1 drugs for weight loss continues to climb, so too are comprehensive management strategies
D., Craig, T
2004;11:S7385
US$ 28.84
US$ 26.84
US$ 26.72
US$ 20.08
US$ 23.95
US$ 24.22
